Arginase inhibitor in the pharmacological correction of endothelial dysfunction.
about
Impact of substrate protonation and tautomerization states on interactions with the active site of arginase I.Pharmacokinetics and Pharmacodynamics of Promising Arginase Inhibitors.Effects of serum uric acid levels on the arginase pathway in women with metabolic syndrome.Study of Endothelial Protective Activity of Phenol-Derived Thrombin and Arginase-2 Inhibitors KUD-259 and KUD-974.The Involvement of Arginase and Nitric Oxide Synthase in Breast Cancer Development: Arginase and NO Synthase as Therapeutic Targets in Cancer.
P2860
Arginase inhibitor in the pharmacological correction of endothelial dysfunction.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Arginase inhibitor in the pharmacological correction of endothelial dysfunction.
@en
type
label
Arginase inhibitor in the pharmacological correction of endothelial dysfunction.
@en
prefLabel
Arginase inhibitor in the pharmacological correction of endothelial dysfunction.
@en
P2093
P2860
P50
P356
P1476
Arginase inhibitor in the pharmacological correction of endothelial dysfunction
@en
P2093
Anna V Babko
Elena A Konovalova
Elena G Terehova
Eleonora N Dudina
Liliya V Korokina
Mihail V Pokrovskiy
Svetlana A Tsepeleva
Vladimir I Kochkarov
Vladimir V Gureev
P2860
P304
P356
10.4061/2011/515047
P577
2011-06-15T00:00:00Z